Meeting
2021 ASCO Annual Meeting
Machine learning models to quantify HER2 for real-time tissue image analysis in prospective clinical trials.
Authors
Benjamin Glass
PathAI, Inc, Boston, MA
Benjamin Glass , Michel Erminio Vandenberghe , Surya Teja Chavali , Syed Ashar Javed , Marlon Rebelatto , Shamira Sridharan , Hunter Elliott , Sudha Rao , Michael Montalto , Murray Resnick , Ilan Wapinski , Andrew Beck , Craig Barker
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Molecular Diagnostics and Imaging
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 3061)
DOI
10.1200/JCO.2021.39.15_suppl.3061
Abstract #
3061
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Evolution of HER2 scores after neoadjuvant systemic therapy in breast cancer.
First Author: Esther G Chong
Poster
2023 ASCO Annual Meeting
ERBB2 mRNA expression to distinguish HER2-low/neg breast cancer prognosis.
First Author: Yueping Liu
Poster
2023 ASCO Annual Meeting
AI-based HER2-low IHC scoring in breast cancer across multiple sites, clones, and scanners.
First Author: Patrick Frey
Poster
2020 ASCO Virtual Scientific Program
Targeted next generation sequencing to expand HER2 status detection: Implication for newer HER2-directed agents.
First Author: Ning Liao